Colleagues of Eleftherios Milonakis from Houston Methodist Hospital conducted a retrospective cohort study. They found that the use of glucagon-like peptide-1 (GLP-1) agonists is associated with lower probabilities of decompensation, hospitalization, and mortality in elderly individuals suffering from metabolic dysfunction-associated fatty liver disease.
Data from the TriNetX network, covering 43,930 patients over 65 years old, were used for the study. The average age of this group was 71.8 years, and 62 percent of them were women. The researchers compared a group of patients who started GLP-1 agonist therapy with a similar group that did not receive these drugs, using a 1:1 propensity score matching method.
The association between treatment and clinical outcomes was assessed using Cox proportional hazards models. The results obtained were officially published in the scientific journal Age and Ageing.